DBV Technologies S.A. (DBVT) Price Target Raised to $56.00
A number of other analysts have also recently commented on the company. Zacks Investment Research cut DBV Technologies from a buy rating to a hold rating in a research report on Friday, September 8th. Morgan Stanley reiterated an overweight rating on shares of DBV Technologies in a research report on Monday, July 10th. Jefferies Group LLC reiterated a buy rating and set a $51.00 target price on shares of DBV Technologies in a research report on Tuesday, September 12th. ValuEngine cut DBV Technologies from a hold rating to a sell rating in a research report on Friday, June 30th. Finally, Leerink Swann raised their price target on DBV Technologies from $54.00 to $60.00 and gave the stock an outperform rating in a report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. DBV Technologies presently has a consensus rating of Buy and an average price target of $56.29.
Shares of DBV Technologies (DBVT) opened at 49.36 on Friday. The stock’s market cap is $2.27 billion. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $50.57. The firm’s 50-day moving average price is $44.22 and its 200 day moving average price is $38.84.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/12/dbv-technologies-s-a-dbvt-price-target-raised-to-56-00.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in shares of DBV Technologies during the first quarter worth about $1,120,000. Bank of America Corp DE grew its holdings in shares of DBV Technologies by 86.3% during the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock worth $936,000 after buying an additional 12,309 shares during the last quarter. Morgan Stanley grew its holdings in shares of DBV Technologies by 89.9% during the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of DBV Technologies during the second quarter worth about $90,724,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of DBV Technologies during the first quarter worth about $3,566,000. 45.52% of the stock is currently owned by hedge funds and other institutional investors.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.